Online applications with CDSCO: DCGI issues clarification on fee submission

Published On 2020-03-16 08:54 GMT   |   Update On 2020-03-16 09:03 GMT

New Delhi: Through a recent notice Central Drugs Standard Control Organization(CDSCO), Directorate General of Health Services has released a clarification for utilization of same fees in case of an inadvertent submission of online applications along with fees meant for a specific division submitted to other division of CDSCO.

The clarification was given by Dr V G Somani, Drugs Controller General (India) (DCGI) through a notice on its website with a copy CDAC with a request to make appropriate system in Sugam Portal so that fees submitted in one division of CDSCO can be utilized by concerned division after the declaration of such inadvertent submission either by the applicant or by the division of CDSCO, HQ & publish the procedure. 

The applicants are required to submit their applications along with fees in different Divisions of this Directorate for obtaining various permissions/approvals. In this light the CDSCO noted

It has been observed that many a time, an applicant submit their online applications inadvertently to a division/section not related to that application (e.g. New Drug Division, FDC Division, GCT Division, Import & Registration Division, etc.) Therefore, in order to ensure transparency, accountability & streamlining of the regulatory process for ease of doing business, it is to clarify that the fees paid for such application can be considered for submission and processing of that application in the related division of CDSCO, HQ after such application has been declared by applicant or CDSCO as inadvertent and not related to division applied for.

For the full details, please click on the link given below:

https://business.medicaldialogues.in/pdf_upload/pdf_upload-125473.pdf


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News